LeonaBio, Inc. filed a current report on Form 8-K on September 22, 2026, disclosing that warrants issued in a December 2025 private placement became exercisable on September 18, 2026, and will remain exercisable until October 19, 2026.

Key Highlights

  • Warrants issued: LeonaBio issued warrants to purchase an aggregate of 23,031,494 shares of common stock as Series A Common Warrants in December 2025.
  • Exercise price: The Series A Common Warrants carry an exercise price of $6.35 per share.
  • Exercise window: The warrants became exercisable on September 18, 2026, and expire on October 19, 2026.
  • Potential proceeds: If exercised in full for cash, the warrants would provide the company with approximately $146.2 million of additional capital, according to the filing.
  • Cashless exercise risk: The company disclosed that warrants may be exercised on a cashless net exercise basis if its resale registration statement is not then effective, providing less or no cash proceeds.

LeonaBio Discloses Exercisability of $146.2 Million Series A Warrant Tranche

LeonaBio, Inc. (NASDAQ:LONA), headquartered in Bothell, Washington, reported under Item 8.01 (Other Events) that its Series A Common Warrants, originally issued in December 2025 as part of a private placement, became exercisable on September 18, 2026. The warrants cover an aggregate of 23,031,494 shares of common stock at an exercise price of $6.35 per share. The filing states the warrants will remain exercisable until October 19, 2026, in accordance with their terms and conditions.

According to the filing, if the Series A Common Warrants were exercised in full for cash, the company would receive approximately $146.2 million of additional capital. The filing characterizes this figure as forward-looking and notes it is subject to risks and uncertainties. Specifically, the company disclosed that some or all of the warrants may expire unexercised, or may be exercised on a cashless net exercise basis in the event the resale registration statement covering the underlying shares is not then effective, which could result in less or no cash proceeds to the company.

The filing was signed by Mark Litton, President and Chief Executive Officer, on September 22, 2026. The company noted that the forward-looking statements regarding potential proceeds speak only as of the date of the filing and that LeonaBio undertakes no obligation to update them except as required by law.

What Was Disclosed

LeonaBio reported that 23,031,494 Series A Common Warrants, issued in a December 2025 private placement at $6.35 per share, became exercisable on September 18, 2026, and will expire on October 19, 2026, with full cash exercise potentially providing approximately $146.2 million in proceeds.